× Medicines Discovery Catapult

Stem cells and organoids… what’s all the fuss about?

Just a few years ago the idea of stem cells was seen more as science fiction than science fact. The general public as a whole didn’t really know what stem cells were, or why they were being used. Even today, when speaking to people outside of the life sciences area about my work, they often […]

Read more

Is it AI, or is it good old-fashioned statistics?

The power of Artificial Intelligence to drive cars, accurately diagnose diseases, recognise cats on the internet, and augment human faces with cartoon rabbit ears is driving a huge wave of interest in the field – Including how it can enable drug discovery. Investment inevitably tends to follow, and consequently the tendency to rebrand many techniques […]

Read more

Helping the drug discovery community deliver

Our CEO, Chris Molloy, attended the Delivering novel therapies in the 21st century meeting at The Royal Society from 24th – 25th October 2018. Here, he shares his key learnings from the event – and what they mean for drug discovery. Drug discovery is still failing too often: new treatment types are outdating the ‘white […]

Read more

Building an ecosystem to support data-driven health startups

The UK is in an excellent position to establish a world-leading position in the field of data-driven health. Technologies such as machine learning, computer vision, and neural networks will accelerate drug discovery by measuring and characterising target engagement, validating targets in translatable cell models, improving our understanding of drugs, disease and drug-target interactions within patients. […]

Read more

Writing a winning grant application

Bidding for grants and funding can be a very frustrating, tiresome and demoralising process. Hours can be wasted putting pen to paper, just so your dreams can be shattered months later after “so-called” experts and faceless bureaucrats tear your hard work apart. Of course, this is all part of the democratic process required to justify […]

Read more

On-demand sampling

The majority of biobank samples are collected as surgical excess, diagnostic remnants or post mortem tissue. While all of these sources are extremely valuable, they each have limitations. Surgical excess and diagnostic samples come from diseased patients, often cancer donors, and the closest to a ‘normal’ sample is adjacent tissue – that is, tissue obtained […]

Read more

Virtual Biobanks

Virtual biobanks do not store samples but provide a single point of access to a range of biospecimens using networks of ethical sources. They source tissues to client specifications – thereby streamlining the procurement of tissue to the benefit of all parties. Real and virtual biobanks have a two-way relationship that works to the advantage […]

Read more

The rise of Biobanks

High quality human tissue samples have become the gold standard for biomedical research, and reliable access to such material is a critical resource for many companies. In addition, the rapid growth of translational research and personalised medicine has further increased demand for human biological samples. Biobanking has been identified as a key area to accelerate […]

Read more

Patients band together to develop their own drugs

A real-world case study to set the scene Timothy Omer is a Type 1 diabetic and a ‘health hacker’. He, and others affected by this debilitating condition, have banded together under the #WeAreNotWaiting banner to develop their own solutions to their health issues. They have lost patience with an industry apparently failing to find answers […]

Read more

Science & Technology

Informatics

Virtual R&D

Discovery Syndicates

Samples and Data